Dr Kadon K Hintz, MD | |
300 N 7th St, Bismarck, ND 58501-4439 | |
(701) 323-6000 | |
Not Available |
Full Name | Dr Kadon K Hintz |
---|---|
Gender | Male |
Speciality | Emergency Medicine |
Location | 300 N 7th St, Bismarck, North Dakota |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1245437730 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | 11559 (North Dakota) | Primary |
Entity Name | Sanford Bismarck |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1811941172 PECOS PAC ID: 9739098575 Enrollment ID: O20031105000403 |
News Archive
Researchers at the University of California, San Diego School of Medicine have identified a therapeutic target for treating the most common form of eye cancer in adults. They have also, in experiments with mice, been able to slow eye tumor growth with an existing FDA-approved drug.
The controversy surrounding GlaxoSmithKline's (GSK) diabetes drug Avandia has been exacerbated by claims from a medical expert that he was threatened with a $4bn lawsuit to try to silence his criticisms of the company's controversial diabetes drug.
Genetically engineered mice, created at the University of Michigan Medical School, are living every dieter's dream.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, and TheraTarget, Inc., a developer of innovative polymer therapeutics for the treatment of cancer, today announced the formation of a joint research collaboration agreement.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Kadon K Hintz, MD Po Box 5501, Bismarck, ND 58506-5501 Ph: (701) 323-6000 | Dr Kadon K Hintz, MD 300 N 7th St, Bismarck, ND 58501-4439 Ph: (701) 323-6000 |
News Archive
Researchers at the University of California, San Diego School of Medicine have identified a therapeutic target for treating the most common form of eye cancer in adults. They have also, in experiments with mice, been able to slow eye tumor growth with an existing FDA-approved drug.
The controversy surrounding GlaxoSmithKline's (GSK) diabetes drug Avandia has been exacerbated by claims from a medical expert that he was threatened with a $4bn lawsuit to try to silence his criticisms of the company's controversial diabetes drug.
Genetically engineered mice, created at the University of Michigan Medical School, are living every dieter's dream.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, and TheraTarget, Inc., a developer of innovative polymer therapeutics for the treatment of cancer, today announced the formation of a joint research collaboration agreement.
› Verified 7 days ago
Steven Sonnamaker, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-4250 | |
Amy Jo Doll, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 | |
Dr. Paul G Grooms, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 | |
Damon L Nelson, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7000 | |
Dr. Jeffrey A Rundio, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-6150 | |
Alistair G Fyfe, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 Fax: 701-323-5709 |